Company Overview and News
CannTrust Holdings (OTC: OTC:CNTTF) is a Canadian based producer of medical cannabis with distribution in Canada, Denmark and Australia. In addition, the company plans to branch into the recreational and pet markets. We believe that the management team’s experience and conservative approach will stand them in good stead as competition heats up. The stock’s price is low among peers.
STZ.B TWMJF WEED ADWPF STZ CGC DEO
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
STZ.B KHRNF RCI ACBFF DTK TXCX STZ CGC RCIAF TWMJF ACB BLK APH WEED APHQF OGRMF GWP OGI
Constellation Brands Inc. (STZ - Free Report) continues its strides to retain its third position in the high-end U.S. beer market through the latest buyout of Dallas, TX-based Four Corners Brewing LLC for an undisclosed amount. The company’s previous efforts to shine in the beer space are highlighted by the acquisition of Funky Buddha Brewery in 2017, Obregon Brewery in 2016, and Ballast Point Brewing & Spirits in 2015.
STZ.B BREW ADI STZ SAM
The legalization of recreational marijuana in Canada will mean new opportunities for cannabis businesses — and that could include pot-infused beverages, Canopy Growth CEO Bruce Linton told CNBC on Wednesday.
STZ.B TWMJF WEED STZ CGC
VICTOR, N.Y., July 10, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today its purchase of Four Corners Brewing LLC ("Four Corners"), reinforcing its strategy to lead the high-end in the U.S. beer market. Grounded in Texas roots and heritage, this high-performing, dynamic and bicultural (Hispanic and American) brand produces beer that’s refreshing, big on flavor and complements Constellation’s existing portfolio.
STZ.B STZ BBOX
Constellation Brands (NYSE:STZ) has grown earnings at a pace of over 20 percent over the last five years, so when it missed earnings in a big way in the last quarter, the stock got hammered.
I recently published a piece highlighting Brown-Forman's (BF.A) (BF.B) weakness, though noting that I think shares are still expensive. I'm a bull on the alcoholic industry on the whole, and I follow a variety of stocks within. The theme is close, but not close enough that I covered regard weakness, and valuation relative to my price target isn't unique to Brown-Forman in the alcohol space. Constellation Brands (STZ) is another one of my favorite beer/wine/liquor names.
TAP STZ.B TWMJF BUD WEED AHBIF STZ CGC
If you’re expecting an article on why Canopy Growth (NYSE:CGC) is undervalued or overvalued, you’ve come to the wrong place because, in my opinion, it’s way too early to put an intrinsic value on CGC stock.
STZ.B TWMJF WEED STZ CGC
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET